Moderated Poster Session II: Prevention and health policy

Abstract

M135 Metabolic syndrome is a predictor of outcome in patients with familial combined hyperlipidemia CMasoura, J Skoumas, K Aznaouridis, VMetaxa, F Platsouka, L Papadimitriou, C Pitsavos, C Stefanadis Athens, Greece Topic: Lipids and atherosclerosis Purpose: Familial combined hyperlipidemia (FCH) is a polygenic lipid disorder associated with premature cardiovascular disease. It is unknown whether metabolic syndrome (MetS) modulates cardiovascular risk in FCH patients. Methods: We studied prospectively 644 FCH patients (421 men) for 9.2 3.6 years. Demographic characteristics and biochemical parameters were evaluated at enrolment, before the initiation of treatment. The diagnosis of MetS was based on the modified ATP III criteria (glucose >100 mg/dl). Hard cardiovascular end-points, like acute myocardial infarction (AMI) and cardiovascular death, were recorded during the follow-up. Results: The 323 patients with MetS were older (50.8 10.2 vs. 46.7 11.0 years, öÀ<0.001) and had higher triglyceride and glucose levels, but they had lower HDL-C levels compared with patients without MetS (all öÀ<0.001). There was no difference in total cholesterol. The combined endpoint (AMI/death) occurred in 29 patients with MetS and in 9 patients without MetS (9.0% vs. 2.8%, P=0.001). Kaplan-Meier analysis showed a significant difference in the event-free survival between the 2 groups (P=0.005, figure). Multivariate analysis (Cox regression) showed that MetS at enrolment predicts AMI/death independent of age, sex or previous cardiovascular disease (adjusted odds ratio 2.25, 95% CI 1.06-4.75, P=0.034). Conclusions: MetS represents an independent predictor of major cardiovascular events in FCH patients.